Systemic metabolic syndrome significantly increases the risk of morbidity and mortality in
patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis …

Nonalcoholic fatty liver disease (NAFLD) encompasses a disease continuum from simple
steatosis to nonalcoholic steatohepatitis (NASH). However, there are currently no approved …

Tripartite motif 8 (TRIM8), an E3 ligase ubiquitously expressed in various cells, is closely
involved in innate immunity. However, its role in nonalcoholic steatohepatitis is largely …

Obesity is considered as a major cause for the development and progress of non-alcoholic
fatty liver disease (NAFLD), which is one of the most prevalent chronic liver diseases …

Nonalcoholic steatohepatitis (NASH)-related hepatocellular carcinoma and liver disorders
have become the leading causes for the need of liver transplantation in developed …

Non-alcoholic steatohepatitis (NASH) is an increasingly prevalent liver pathology that can
progress from non-alcoholic fatty liver disease (NAFLD), and it is a leading cause of cirrhosis …

Background and Aims NAFLD is the most prevalent chronic liver disease worldwide, but no
effective pharmacological therapeutics are available for clinical use. NASH is the more …

Sterol regulatory element binding protein1c (SREBP1c) is a key transcription factor for de
novo lipogenesis during the postprandial state. During nutritional deprivation, hepatic …

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease around the
world. However, no specific medicine has been approved for NAFLD treatment. Our study …

Background & Aims Aberrantly high expression of TRIM24 occurs in human cancers,
including hepatocellular carcinoma. In contrast, TRIM24 in the mouse is reportedly a liver …